Home / Market News / $INO
fiscal.ai Corporate Catalyst Impact 55/100 ● positive

Piper Sandler Maintains Buy Rating on Inovio Pharmaceuticals and Raises Price Target

Nov 12, 2026, 2:15 PM UTC · Primary ticker $INO

Piper Sandler reaffirmed its 'Buy' rating for Inovio Pharmaceuticals and increased its price target from $4 to $6. This analyst action signals a more positive outlook on the company's future performance, which could lead to increased investor interest and a potential short-term bump in stock price.

Piper Sandler analyst Edward Tenthoff reaffirmed a 'Buy' rating for Inovio Pharmaceuticals and raised the price target from $4 to $6. This analyst upgrade suggests increased confidence in Inovio's prospects, likely driven by recent developments or anticipated milestones not detailed in this filing. For traders, this could lead to short-term positive momentum for INO stock as investors react to the more optimistic outlook. The long-term implications depend on whether the company can meet the expectations implied by the higher price target. A key opportunity for traders is to capitalize on potential upward price movement, while the risk lies in the possibility that the market has already priced in this analyst action or that future company performance fails to justify the new target.

$INO positive Analyst rating upgrade and price target increase
Source: fiscal.ai
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.